SFX by Ex Libris Inc.

Title:	Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Source:	Nature [0028-0836] Yadav, M yr:2014

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Gubin, M. "Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens." Nature 515.7528 (2014): 577-81.
description	2.	Dupage, M. "Expression of tumour-specific antigens underlies cancer immunoediting." Nature 482.7385 (2012): 405-409.
description	3.	Yang, Mark A. "Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer." Science 344.6184 (2014): 641-645.
description	4.	Prelusky, D B B. "The effect of deoxynivalenol on serotoninergic neurotransmitter levels in pig blood." Journal of environmental science and health. Part B, pesticides, food contaminants, and agricultural wastes 29.6 (1994): 1203-18.
description	5.	Banchereau, J. "Dendritic cells as therapeutic vaccines against cancer." Nature reviews. Immunology 5.4 (2005): 296-306.
description	6.	Matsushita, H. "Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting." Nature 482.7385 (2012): 400-404.
description	7.	Vesely, Matthew D. "Natural Innate and Adaptive Immunity to Cancer." Annual review of immunology 29.1 (2010): 235-271.
description	8.	West, A. "PD-1 blockade induces responses by inhibiting adaptive immune resistance." Nature 515.7528 (2014): 568-571.
description	9.	Powles, T. "MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer." Nature 515.7528 (2014): 558-62.
description	10.	Mittal, D. "New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape." Current opinion in immunology 27.1 (2014): 16-25.
description	11.	RD, S. "Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion." Science 331.6024 (2011): 1565-70.
description	12.	Dunn, Gavin P P. "Cancer immunoediting: from immunosurveillance to tumor escape." Nature immunology 3.11 (2002): 991-8.
description	13.	Byrd, John C. "A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia." Blood 123.9 (2014): 1302-1308.
description	14.	Gattinoni L, L. "Adoptive immunotherapy for cancer: building on success." Nature reviews. Immunology 6.5 (2006): 383-393.
description	15.	Rosenberg, Steven A. "Adoptive cell transfer as personalized immunotherapy for human cancer." Science 348.6230 (2015): 62-68.
description	16.	Pollack, Ian F. "Antigen-Specific Immune Responses and Clinical Outcome After Vaccination With Glioma-Associated Antigen Peptides and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Children With Newly Diagnosed Malignant Brainstem and N." Journal of clinical oncology 32.19 (2014): 2050-8.
description	17.	Song, M. "A critical role of vascular endothelial growth factor D in zebrafish embryonic vasculogenesis and angiogenesis." Biochemical and biophysical research communications 357.4 (2007): 924-30.
description	18.	Hackstein, H. "Dendritic cells: emerging pharmacological targets of immunosuppressive drugs." Nature reviews. Immunology 4.1 (2003): 24-34.
description	19.	Banchereau, J. "Taking dendritic cells into medicine." Nature 449.7161 (2007): 419-26.
description	20.	Freeman, GJ J. "Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation." The Journal of experimental medicine 192.7 (2000): 1027-1034.